NCT06737016View on ClinicalTrials.gov

Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.

PHASE3RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

November 30, 2026

Conditions
Posterior Urethral Valve
Interventions
DRUG

Tamsulosin

Children will be maintained on an oral dose of Tamsulosin 0.1 mg once daily (in children aged less than 2 years old) and 0.2 mg once daily (≥2 years old).

DRUG

Oxybutynin

Children will be maintained on an oral dose of Oxybutynin 0.2 mg/kg 2 times daily.

DRUG

Trimethoprim/sulfamethoxazole (TMP/SMZ)

Children will be maintained on an oral prophylactic dose of Trimethoprim/sulfamethoxazole 2 mg/kg single dose at night.

Trial Locations (1)

35511

RECRUITING

Mansoura Urology and Nephrology Center, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER